Skip to main content

Table 3 Incidence of treatment-emergent adverse events occurring in > 2% of patients

From: 2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

Preferred Term

2-DG 63 mg + SOC

N = 22

SOC1

N = 22

2-DG 90 mg + SOC

N = 22

2-DG 126 mg + SOC

N = 21

SOC2

N = 22

SOC (SOC1 + SOC2)

N = 44

Total

N = 109

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Hyperglycaemia

1 (4.5)

2 (9.1)

1 (4.5)

2 (9.5)

4 (18.2)

6 (13.6)

10 (9.2)

Palpitations

2 (9.1)

0

2 (9.1)

0

0

0

4 (3.7)

Dizziness

2 (9.1)

0

2 (9.1)

0

0

0

4 (3.7)

Diarrhea

1 (4.5)

0

2 (9.1)

0

0

0

3 (2.8)

Hyperhidrosis

2 (9.1)

0

0

1 (4.8)

0

0

3 (2.8)

  1. 2-DG 2-deoxy-d-glucose, SOC standard of care, SOC1 SOC in Part A of the study, SOC2 SOC in Part B of the study
  2. N: Total number of patients in the specified treatment group
  3. n: Number of patients with the adverse events of the preferred term